Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06845319 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 0 to 1 · Primary completion date: Jun 30, 2027 to Oct 20, 2027 · Completion date: Jun 30, 2028 to Oct 20, 2028 · 2 morev6Show 5 more changesShow less
Study sites: 0 to 1
Primary completion date: Jun 30, 2027 to Oct 20, 2027
Completion date: Jun 30, 2028 to Oct 20, 2028
Start date changed from estimate of Nov 1, 2025 to Oct 20, 2025
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who are ineligible for anthracycline-based therapy due to underlying cardiac conditions.